Zhang ML, Ran LQ, Wu MJ, Jia QC, Qin ZM, Peng YG. NF-κB: A novel therapeutic pathway for gastroesophageal reflux disease? World J Clin Cases 2022; 10(24): 8436-8442 [PMID: 36157831 DOI: 10.12998/wjcc.v10.i24.8436]
Corresponding Author of This Article
Zhi-Ming Qin, MS, Assistant Professor, Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, China, Chongqing 400042, China. Qzm201596@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Opinion Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Mao-Lin Zhang, Zhi-Ming Qin, Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China
Long-Qing Ran, Meng-Jun Wu, Department of Anesthesia, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610019, China
Qin-Chen Jia, Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China
Yong G Peng, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, FL 32610, United States
Author contributions: Zhang ML and Ran LQ contributed equally to this work, They edited the article together; Wu MJ provided writing guidance for this paper; Jia QC collected and organized the articles; Yong GP polished the language of the article; Qin ZM determined the propositional direction of the article; all authors have read and approved the final manuscript.
Conflict-of-interest statement: There is no conflict of interest in this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this worκ non-commercially, and license their derivative worκs on different terms, provided the original worκ is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Ming Qin, MS, Assistant Professor, Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, China, Chongqing 400042, China. Qzm201596@163.com
Received: April 1, 2022 Peer-review started: April 1, 2022 First decision: June 7, 2022 Revised: June 16, 2022 Accepted: July 16, 2022 Article in press: July 16, 2022 Published online: August 26, 2022 Processing time: 136 Days and 13 Hours
Abstract
Although gastroesophageal reflux disease (GERD), a common chronic disease in clinical practice, has been widely studied, its potential adverse impact on patients is still a significant clinical concern. It is necessary to understand the pathogenesis of the disease and choose appropriate treatment according to its mechanism. The pathogenesis of GERD is diverse and complex. As the traditional treatment methods are expensive and ineffective in alleviating symptoms in some patients, new treatment options need to be explored. Our previous study suggested that the activation of nuclear factor-kappa beta (NF-κB) in esophageal mucosa may be related to the injury of epithelial barrier function caused by reflux. Based on the literature and our previous study results, it is speculated that inhibition of NF-κB activation may block the insult of GERD on the esophageal mucosal barrier. NF-κB may play an important role in the development of GERD. This article reviews the pathogenesis of GERD and the relationship between NF-κB and GERD, in order to provide new strategies for the treatment of GERD.
Core Tip: Gastroesophageal reflux disease (GERD) is one of the most common chronic diseases. Current treatments, including drugs and surgery, have significant side effects and some patients do not respond to treatment. This article reviews the pathogenesis of GERD, especially the relationship between the NF-κB pathway and GERD. We also assessed the latest studies on the effects of drugs inhibiting the NF-κB pathway in GERD, providing new possibilities for the treatment of GERD.
